School for Engineering of Matter,
Transport and Energy,
School for Engineering of Matter, Transport and Energy
Michael R. Sierks has not added Biography.
If you are Michael R. Sierks and would like to personalize this page please email our Author Liaison for assistance.
Degradation of beta-amyloid by proteolytic antibody light chains.
Biochemistry Dec, 2003 | Pubmed ID: 14640701
Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation.
Journal of neuroscience research Jan, 2004 | Pubmed ID: 14705137
Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
Biochemistry Mar, 2004 | Pubmed ID: 15005622
Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity.
Biochemistry Jun, 2004 | Pubmed ID: 15170333
Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity.
Biochemistry Aug, 2004 | Pubmed ID: 15287727
A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein.
Molecular therapy : the journal of the American Society of Gene Therapy Dec, 2004 | Pubmed ID: 15564134
Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42.
Neurobiology of disease Oct, 2005 | Pubmed ID: 16137568
Quantification of cytokines involved in wound healing using surface plasmon resonance.
Analytical chemistry Nov, 2005 | Pubmed ID: 16255604
Identification and repair of positive binding antibodies containing randomly generated amber codons from synthetic phage display libraries.
Biotechnology progress May-Jun, 2006 | Pubmed ID: 16739981
Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42.
Biochemistry Sep, 2006 | Pubmed ID: 16981713
Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies.
Protein engineering, design & selection : PEDS Nov, 2006 | Pubmed ID: 16984950
Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Dec, 2006 | Pubmed ID: 17068112
Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.
Journal of molecular biology May, 2007 | Pubmed ID: 17391701
Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy.
Nanomedicine : nanotechnology, biology, and medicine Sep, 2007 | Pubmed ID: 17662669
Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy.
Nanomedicine : nanotechnology, biology, and medicine Mar, 2008 | Pubmed ID: 18201941
Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates.
FEBS letters Feb, 2008 | Pubmed ID: 18230361
Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells.
Journal of molecular biology Dec, 2008 | Pubmed ID: 18929576
Characterizing antibody specificity to different protein morphologies by AFM.
Langmuir : the ACS journal of surfaces and colloids Jan, 2009 | Pubmed ID: 19090748
Detecting morphologically distinct oligomeric forms of alpha-synuclein.
The Journal of biological chemistry Apr, 2009 | Pubmed ID: 19141614
Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells.
Neuroscience letters Jul, 2009 | Pubmed ID: 19394405
Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.
PloS one , 2009 | Pubmed ID: 19492089
Cyclodextrins promote protein aggregation posing risks for therapeutic applications.
Biochemical and biophysical research communications Aug, 2009 | Pubmed ID: 19540204
Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid.
Biotechnology progress Jul-Aug, 2010 | Pubmed ID: 20306540
Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.
Protein engineering, design & selection : PEDS Jun, 2010 | Pubmed ID: 20378699
Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity.
Biochemistry Jun, 2010 | Pubmed ID: 20429609
Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.
BMC neuroscience , 2010 | Pubmed ID: 20433710
Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form.
Neurobiology of aging Jul, 2012 | Pubmed ID: 21067847
Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
Journal of molecular biology Jan, 2011 | Pubmed ID: 21073877
CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.
Integrative biology : quantitative biosciences from nano to macro Dec, 2011 | Pubmed ID: 22076255
Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP.
Journal of Alzheimer's disease : JAD , 2012 | Pubmed ID: 22156046
Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.
Biotechnology progress Mar-Apr, 2013 | Pubmed ID: 23359572
Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein.
PloS one , 2013 | Pubmed ID: 23437071
A Sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples.
Biotechnology progress Sep, 2014 | Pubmed ID: 25203940
Isolation and characterization of antibody fragments selective for toxic oligomeric tau.
Neurobiology of aging Dec, 2014 | Pubmed ID: 25616912
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유